An investigation for investors in NASDAQ:OCUL shares was announced over potential securities laws violations by Bedford, MA based biopharmaceutical company Ocular Therapeutix and certain of its directors and officers.
Investors who purchased shares of Ocular Therapeutix Inc (NASDAQ:OCUL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Ocular Therapeutix regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On June 6, 2016, Ocular Therapeutix Inc announced topline results from its second Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot for the treatment of ocular itching associated with chronic allergic conjunctivitis. Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) declined from $12.43 per share on June 3, 2016 to as low as $4.63 per share on June 27, 2016.
Those who purchased NASDAQ:OCUL shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com